Lentiviral Vectors and Gene Therapy (Record no. 101741)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04998nam a22005775i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-3-0348-0402-8 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220083254.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120321s2012 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783034804028 |
| -- | 978-3-0348-0402-8 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-3-0348-0402-8 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RB155.8 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MFN |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED107000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.895 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Escors, David. |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Lentiviral Vectors and Gene Therapy |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | by David Escors, Karine Breckpot, Frederick Arce, Grazyna Kochan, Holly Stephenson. |
| 264 #1 - | |
| -- | Basel : |
| -- | Springer Basel, |
| -- | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | IX, 104p. 10 illus., 9 illus. in color. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | SpringerBriefs in Biochemistry and Molecular Biology, |
| International Standard Serial Number | 2211-9353 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1 Introduction to gene therapy.- 1.1 The concept of gene therapy -- 1.2 Origins of gene therapy -- 1.3 Gene therapy in the 1970s -- 1.4 Gene therapy in the 1980s -- 1.5 The breakthroughs in gene therapy from the 1990s and 2000s -- 1.6 Current human gene therapy and lentiviral vectors -- 1.7. Concluding remarks.- 2 Development of retroviral and lentiviral vectors.- 2.1 Retrovirus biology -- 2.2 Vectors based on γ -retroviruses -- 2.3 Vectors based on lentiviruses -- 2.4 Summary and conclusions.- 3 Cell and tissue gene targeting with lentiviral vectors -- 3.1 Introduction -- 3.2 Modification of lentivector tropism by pseudotyping (surface targeting) -- 3.3 Transcriptional targeting -- 3.4 Post-transcriptional targeting -- 3.5 Conclusions.- 4 Immunomodulation by genetic modification using lentiviral vectors -- 4.1 Introduction to genetic immunotherapy -- 4.2 Lentivector gene therapy for immunization -- 4.3 Lentivector gene therapy for the treatment of autoimmune disease -- 4.4 Conclusions -- 5 Clinical grade lentiviral vectors.- 5.1 Introduction -- 5.2 Good manufacturing practise guidelines and clinical grade vector preparations -- 5.3 Scaling-up lentivector production for clinical application -- 5.4 Purity of clinical grade lentivectors -- 5.5 Biosafety -- 5.6 Final considerations and conclusions.- 6 Human gene therapy with retrovirus and lentivirus vectors -- 6.1 Introduction -- 6.2 Correction of Severe Combined Immunodeficiency-X1 -- 6.3 Correction of X-linked chronic granulomatous disease -- 6.4 Correction of X-linked adrenoleukodystrophy -- 6.5 Correction of b-thalassaemia -- 6.6 Correction of Wiscott-Aldrich syndrome -- 6.7 Conclusions and final considerations. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Gene therapy was conceived during the early and mid part of the 20th century. At first, it was considered a revolutionary biomedical procedure, which could potentially cure any disease for which the molecular bases were understood. Since then, gene therapy has gone through many stages and has evolved from a nearly unrealistic perspective to a real life application. Clinical efficacy in humans was demonstrated at the beginning of this century after its successful application in small-scale clinical trials to cure severe immunodeficiency in children. However, their successes were overshadowed some time later by the occurrence of vector-related leukaemia in a number of treated children. It is in this context that lentiviral vectors have appeared, with improved efficiency and, possibly, increased biosafety. Very recently, the first clinical trials with lentivectors have been carried out with some success. This Brief firstly defines gene therapy, and places lentivectors within this fascinating therapeutic strategy. Then follows a comprehensive description of the development of retroviral and lentiviral vectors and how to specifically target distinct cell types and tissues. The authors also discuss the application of lentivector gene therapy for the treatment of cancer and autoimmune diseases, ending with the application of lentivectors in human gene therapy clinical trials. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Gene therapy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Immunology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Genetic engineering. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cytology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Gene Therapy. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Immunology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Genetic Engineering. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cell Biology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Breckpot, Karine. |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Arce, Frederick. |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kochan, Grazyna. |
| Relator term | author. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stephenson, Holly. |
| Relator term | author. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9783034804011 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | SpringerBriefs in Biochemistry and Molecular Biology, |
| -- | 2211-9353 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-3-0348-0402-8 |
| 912 ## - | |
| -- | ZDB-2-SBL |
No items available.